Cytomegalovirus immediate-early 1 peptide–Human leukocyte antigen class I complex (CMV IE1-HLA class I complex)

The Cytomegalovirus immediate-early 1 (IE1) peptide–Human leukocyte antigen (HLA) class I complex is a peptide-major histocompatibility complex (pMHC) that plays a pivotal role in the immune recognition of human cytomegalovirus (HCMV). IE1 is a major regulatory protein expressed immediately upon viral entry or reactivation, making it a primary target for CD8+ cytotoxic T lymphocytes (CTLs) (1.5.1). The complex forms when IE1-derived peptides, such as VLEETSVML or CRVLCCYVL, are processed and presented on the cell surface by specific HLA class I alleles like HLA-A*02:01 or HLA-C*07:02 (1.1.2, 1.3.3). This presentation is essential for the activation of the adaptive immune system to control CMV infection, particularly in immunocompromised individuals such as transplant recipients (1.1.1). Therapeutically, this complex is targeted by adoptive T-cell therapies, TCR-like antibodies, and bispecific molecules designed to redirect the immune system against infected or malignant cells (1.3.1, 1.4.1). However, CMV employs sophisticated evasion strategies, including the downregulation of HLA molecules, to avoid detection (1.5.2). Furthermore, the use of therapies targeting these complexes carries risks of off-target toxicity and graft-versus-host disease due to potential TCR cross-reactivity with self-antigens (1.4.5).

Other names

CMV IE1 pMHCHCMV IE1-HLA complexCytomegalovirus IE1 antigen-MHC complexIE1 peptide-HLA class I complexpCMV-IE1/HLA-A2 complex

The complex serves as a specific ligand for T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes. Therapeutic agents, such as TCR-engineered T cells (TCR-T) or TCR-like antibodies, bind to the specific peptide-HLA interface to trigger immune-mediated lysis of CMV-infected or malignant cells (1.3.1, 1.4.1).